Brief: Nurix Therapeutics Presents New Positive Data From Phase 1A/1B Clinical Trial Of NX-5948
09/12/2024 23:05
Dec 10 (Reuters) - Nurix Therapeutics Inc NRIX.O :
* NURIX THERAPEUTICS PRESENTS NEW POSITIVE DATA FROM PHASE
1A/1B
CLINICAL TRIAL OF NX-5948 IN CHRONIC LYMPHOCYTIC LEUKEMIA AT THE
66TH AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING
* NURIX THERAPEUTICS INC - FAVORABLE SAFETY PROFILE ACROSS
ALL
DOSES TESTED
Source text: urn:newsml:reuters.com:*:nGNX7q8r9x
Further company coverage: NRIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nurix Therapeutics
See all newsNurix Therapeutics Q3 swings to profit on Roche collaboration
Brief: Nurix Extends Gilead Collaboration For Oncology Program
Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis